Mass Spectrometry-Based Serum and Plasma Peptidome Profiling for Prediction of Treatment Outcome in Patients With Solid Malignancies

Documenti analoghi

• Selection of Protein Kinase Inhibitors Based on Tumor Tissue Kinase Activity Profiles in Patients with Refractory Solid Malignancies: An Interventional Molecular Profiling Study
  di: Labots, Mariette, et al.
  Pubblicazione: (2018)
• Evaluation of a tyrosine kinase peptide microarray for tyrosine kinase inhibitor therapy selection in cancer
  di: Labots, Mariette, et al.
  Pubblicazione: (2016)
• Limitations of mass spectrometry-based peptidomic approaches
  di: Fricker, Lloyd D.
  Pubblicazione: (2015)
• An optimized informatics pipeline for mass spectrometry-based peptidomics
  di: Wu, Chaochao, et al.
  Pubblicazione: (2015)
• Kinase Inhibitor Treatment of Patients with Advanced Cancer Results in High Tumor Drug Concentrations and in Specific Alterations of the Tumor Phosphoproteome
  di: Labots, Mariette, et al.
  Pubblicazione: (2020)